The comparison of outcomes between hypofractionated and conventional 3D-CRT regimens used in combination with TACE as first-line treatment of advanced hepatocellular carcinoma.

Autor: Wang, Chuanxi, Li, Suping, Sun, Aimin, Chen, Longhua, Liang, Rongxiang, Li, Guanzhen, Han, Junqing
Zdroj: Tumor Biology (Springer Science & Business Media B.V.); Jul2015, Vol. 36 Issue 7, p4967-4972, 6p
Abstrakt: Treatment of primary hepatocellular carcinoma (HCC) with transcatheter hepatic arterial chemoembolization (TACE) and three-dimensional conformal radiotherapy (3D-CRT) achieves good short-term but poor long-term survival. We retrospectively assessed whether outcomes differ between hypofractionated and conventional 3D-CRT regimens. Patients were treated in our institution between June 2005 and October 2009. All patients received two cycles of TACE followed by either hypofractionated 3D-CRT (6-8 Gy fractions for 3-4 weeks to 48-64 Gy) or conventional 3D-CRT (2 Gy fractions for 6-7 weeks to 60-70 Gy) 4 weeks later. We assessed data from 110 patients (55 in each 3D-CRT group). Overall response rates were similar in the two groups. Acute adverse event rates were not significantly higher in the hypofractionated 3D-CRT group than in the conventional 3D-CRT group; two patients and one patient, respectively, died of late radiation-induced liver failure. Overall survival at 1 year was 83.6 % in the hypofractionated 3D-CRT group versus 68.8 % in the conventional 3D-CRT group ( P = 0.019), and at 3 years, it was 31.7 versus 13.9 % ( P = 0.004). Median survival was 27.97 versus 16.13 months ( P = 0.002). Hypofractionated 3D-CRT seemed to provide better overall survival than conventional 3D-CRT regimens combined with TACE as a first-line treatment for advanced HCC. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: